Development of nomogram to non-steroidal antiandrogen sequential alternation in prostate cancer for predictive model

Japanese Journal of Clinical Oncology

Volumn 44, Issue 3, 2014, Pages 263-269

  Kamiya, Naoto ^a   Suzuki, Hiroyoshi ^a,b   Nishimura, Kensaku ^b   Fujii, Motohiro ^b   Okegawa, Takatsugu ^b   Matsuda, Tadashi ^b   Morita, Tatsuo ^b   Takihana, Yoshio ^b   Ozono, Seiichiro ^b   Namiki, Mikio ^b   Matsubara, Akio ^b   Ichikawa, Tomohiko ^b,c   Miki, Tsuneharu ^b,d  

^a TOHO UNIVERSITY   (Japan)

^b Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group   (Japan)

^c CHIBA UNIVERSITY   (Japan)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Alternation; Hormone therapy; Nomogram; Prostate cancer

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; C REACTIVE PROTEIN; GOSERELIN; HEMOGLOBIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ANTIGEN DETECTION; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; DRUG EFFICACY; GLEASON SCORE; HEMOGLOBIN BLOOD LEVEL; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; NOMOGRAM; PROSTATE CANCER; PROSTATE SURGERY; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; ALTERNATION; BLOOD; CANCER GRADING; DISEASE COURSE; DRUG ADMINISTRATION; HORMONAL THERAPY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PREDICTIVE VALUE; PROSTATE TUMOR; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; TUMOR RECURRENCE; VALIDATION STUDY;

ALTERNATION; HORMONE THERAPY; NOMOGRAM; PROSTATE CANCER;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; C-REACTIVE PROTEIN; COHORT STUDIES; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; GOSERELIN; HUMANS; KAPLAN-MEIER ESTIMATE; LEUPROLIDE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84899475191     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt230     Document Type: Article

References (26)

1. Cancer Registration Committee of the Japanese Urological Association: Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 2005;12:46-61.
2. Suzuki H, Kamiya N, Imamoto T, et al. Current topics and perspectives relating to hormone therapy for prostate cancer. Int J Clin Oncol 2008;13:401-10.
3. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the FLT withdrawal syndrome. J Urol 1993;149:607-9.
4. Lam JS, Leppert JT, Vemulapalli SN, et al. Secondary hormonal therapy for advanced prostate cancer. J Urol 2006;175:27-34.
5. Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology 1995;46:142-8.
6. Joyce R, Fenton MA, Rode P, et al. High dose BCL for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998;159:149-53.
7. Kojima S, Suzuki H, Akakura K, et al. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 2004;171:679-83.
8. Suzuki H, Okihara K, Miyake H, et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that has relapsed after initial maximum androgen blockade. J Urol 2008;180:921-7.
9. Kattan MW, Shariat SF, Andrews B, et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 2003;21:3573-9.
10. Attard G, Belldegrun AS, Bono JS. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 2005;96:1241-6.
11. Suzuki H, Komiya A, Kamiya N, et al. Development of a nomogram to predict probability of positive initial prostate biopsy among Japanese patients. Urology 2006;67:131-6.
12. Kawamura K, Suzuki H, Kamiya N, et al. Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL. Int J Urol 2008;15:598-603.
13. Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988;61:195-202.
14. Akaza H, Yamaguchi A, Matsuda T, et al. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Jpn J Clin Oncol 2004;34:20-8.
15. Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2006;25:1596-605.
16. Scher HI, Eisenberger M, D'Amico AV, et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the prostate-specific antigen working group. J Clin Oncol 2004;22:537-56.
17. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 2000;355:1491-8.
18. Klotz L. Combined androgen blockade in prostate cancer: meta-analyses and associated issues. BJU Int 2001;87:806-13.
19. Miyake H, Hara I, Eto H. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU Int 2005;96:7951-5.
20. Hara T, Miyazaki J, Arai H, et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003;63:149-53.
21. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;9:401-6.
22. Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332:1393-8.
23. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-25.
24. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-54.
25. Guo Z, Yang X, Sun F, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009;69:2305-13.
26. Leibowitz-Amit R, Joshua AM. Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. Curr Oncol 2012;19:22-31.